Aspirin use may improve survival for bladder and breast cancer, according to a study published in JAMA Network Open. Researchers investigated the association of aspirin use with the risk for developing new cancers, as well as site-specific cancer-associated survival for bladder, breast, esophageal, gastric, pancreatic, and uterine cancers in an analysis of 139,896 individuals (mean age, 66.4). Aspirin use was not associated with the incidence of any studied cancer type. Aspirin use at least three times/ week was associated with increased survival among patients with bladder (hazard ratio [HR], 0.67) and breast (HR, 0.75) cancers. However, there was no survival benefit with esophageal, gastric, pancreatic, or uterine cancers. A similar association for bladder and breast cancer was seen for any aspirin use (HRs, 0.75 and 0.79, respectively).
